PROSTATE HEALTH INDEX PHI Test
The Prostate Health Index (PHI) test is a blood test used to assess the risk of prostate cancer in men. It combines the results of three different prostate-specific antigen (PSA) tests to provide a more accurate evaluation of the likelihood of having prostate cancer.
Test Details
The PHI test measures three types of PSA in the blood: total PSA, free PSA, and proPSA. By analyzing the ratio of these three PSA forms, the PHI test can help differentiate between prostate cancer and benign conditions, such as an enlarged prostate or inflammation.
The PHI test is typically recommended for men with elevated PSA levels (between 4 and 10 ng/mL) and a negative digital rectal examination (DRE). It can provide additional information to guide further diagnostic procedures, such as a prostate biopsy, or to monitor the progression of prostate cancer in men with a confirmed diagnosis.
Compared to the traditional PSA test, the PHI test has shown improved specificity and accuracy in identifying aggressive prostate cancer, while reducing unnecessary biopsies for men with benign conditions. However, it is important to note that the PHI test is not a definitive diagnostic tool and should be used in conjunction with other clinical evaluations.
Test Name: PROSTATE HEALTH INDEX PHI Test
Components:
- PSA, Total
- PSA, Free
- P2PSA
Price: 660.0 AED
Sample Condition:
2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Do not draw sample within 7 days of Digital Rectal Examination (DRE) or Rectal Prostatic Ultrasonography.
Report Delivery:
Sample Mon / Thu by 4 pm; Report Same day
Method: CMIA, CLIA
Test type: Prostate Cancer
Doctor: Oncologist
Test Department: THYROID & HORMONES
Pre Test Information:
Do not give sample within 7 days of Digital Rectal Examination (DRE) or Rectal Prostatic Ultrasonography.
It is recommended to consult with a healthcare professional to determine if the PHI test is appropriate for individual circumstances and to interpret the results accurately.
Test Name | PROSTATE HEALTH INDEX PHI Test |
---|---|
Components | *PSA,Total*PSA,Free*P2PSA |
Price | 660.0 AED |
Sample Condition | 2 mL (1 mL min.) serum from 1 SST. Shiprefrigeratedorfrozen.Donotdraw samplewithin7daysofDigitalRectal Examination (DRE) or Rectal Prostatic Ultrasonography. |
Report Delivery | SampleMon / Thu by 4 pm; Report Same day |
Method | CMIA, CLIA |
Test type | Prostate Cancer |
Doctor | Oncologist |
Test Department: | THYROID & HORMONES |
Pre Test Information | Donot give samplewithin7daysofDigitalRectal Examination (DRE) or Rectal Prostatic Ultrasonography. |
Test Details |
The Prostate Health Index (PHI) test is a blood test used to assess the risk of prostate cancer in men. It combines the results of three different prostate-specific antigen (PSA) tests to provide a more accurate evaluation of the likelihood of having prostate cancer. The PHI test measures three types of PSA in the blood: total PSA, free PSA, and proPSA. By analyzing the ratio of these three PSA forms, the PHI test can help differentiate between prostate cancer and benign conditions, such as an enlarged prostate or inflammation. The PHI test is typically recommended for men with elevated PSA levels (between 4 and 10 ng/mL) and a negative digital rectal examination (DRE). It can provide additional information to guide further diagnostic procedures, such as a prostate biopsy, or to monitor the progression of prostate cancer in men with a confirmed diagnosis. Compared to the traditional PSA test, the PHI test has shown improved specificity and accuracy in identifying aggressive prostate cancer, while reducing unnecessary biopsies for men with benign conditions. However, it is important to note that the PHI test is not a definitive diagnostic tool and should be used in conjunction with other clinical evaluations. It is recommended to consult with a healthcare professional to determine if the PHI test is appropriate for individual circumstances and to interpret the results accurately. |